Alphamab Oncology is a biopharmaceutical company dedicated to the development, manufacturing and commercialization of cutting-edge innovative biotherapeutics for cancer treatment. On December 12, 2019, Alphamab Oncology was listed on the Main Board of Hong Kong Stock Exchange, trading under the stock code 9966. Our integrated platform seamlessly combines research, development, manufacturing and quality control capabilities for biologics. We take pride in our extensive intellectual property portfolio, which encompasses protein/antibody engineering, antibody screening, and multi-module/multi-functional antibody modification. By leveraging its unique and leading proprietary technology platforms, Alphamab Oncology has established a differentiated and globally competitive product portfolio covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies.
We are actively looking for partners in the following areas:
Cooperation based on technology platforms:
● Partnership with our proprietary glycan-specific conjugation, linker-payload, bispecific antibody, subcutaneous high concentration formulation and single-domain antibody platforms.
Collaboration based on innovative products in oncology:
● KN035: PD-L1 single domain antibody, subcutaneous formulation
● KN026: Anti-HER2 bispecific antibody
Collaboration based on innovative products in oncology:
● JSKN003: Anti-HER2 Biparatopic ADC
● JSKN016: HER3/TROP2 Bispecific ADC
● JSKN033: Anti-HER2 Bispecific ADC Subcutaneous Co-formulation
WE ARE NOW OPEN FOR
Licensing
co-development
option deal
M&A
...
OUR PARTNERS
If you have an interest in one of these areas, please direct your inquiry to bd@alphamabonc.com
